BERWYN, PA — Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimer’s disease (AD), Parkinson’s disease (PD) and other neurodegenerative diseases, announced the European Patent Office (EPO) granted the Company’s patent for a method of treating Alzheimer’s disease in humans by administering its lead compound, ANVS401.
“We now have two patents covering our primary disease targets, AD and PD, both originating from a patent family that claims ANVS401 for the treatment of neurodegenerative diseases. Pursuant to our discussions with the US Patent and Trademark Office (USPTO), we split the original application into a number of patents, each one covering individual diseases that our drug targets,” commented Maria Maccecchini, Ph.D., CEO of Annovis. “Based on these discussions, we have filed additional patent applications for each individual neurodegenerative disease and expect to receive additional patent allowances in the coming months. We will continue to provide further updates as we execute on this process.”
The USPTO approved the Company’s first PD patent (US 10,383,851) in August 2019. The EPO approved Annovis Bio’s first AD patent (EP 2683242) on March 12, 2020.
ANVS401 can work in AD and PD because nerve cells die by the same mechanism in both diseases, and ANVS401 stops the toxic cascade leading to nerve cell death in both diseases. Capitalizing on that knowledge, Annovis Bio is running two Phase 2 studies to show in both patient populations that what was demonstrated in animals can be reproduced in humans and that ANVS401 protects the nerve cells from dying, and by doing so, preserves the associated function.
Thanks for visiting! MyChesCo brings reliable information and resources to Chester County, Pennsylvania. Please consider supporting us in our efforts. Your generous donation will help us continue this work and keep it free of charge. Show your support today by clicking here and becoming a patron.
Disclosure: This site contains affiliate links to products. MyChesCo may receive a commission for purchases made through these links.